Seagull Laboratories Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Seagull Laboratories Pharmaceutical Export Portfolio Dataset — 2 Products, $253.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Seagull Laboratories — Pharmaceutical Exporter Profile (2026) | 2 Products, $253.4K Trade | TransData Nexus

Seagull Laboratories

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $253.4K Total Trade · DGFT Verified

Seagull Laboratories is an Indian pharmaceutical exporter with a total trade value of $253.4K across 2 products in 2 therapeutic categories. Based on 9 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Hydroxychloroquine ($153.3K), Melphalan ($100.1K), .

Seagull Laboratories — Export Portfolio & Destination Treemap

Seagull Laboratories pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Seagull Laboratories? — Company Overview & Market Position

Seagull Laboratories (India) Private Limited, established on May 12, 1981, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U74899DL1981PTC011698. As of March 31, 2022, Seagull Laboratories reported a total revenue of approximately $1.7 million USD, reflecting a 26.5% year-over-year growth. The company's authorized capital stands at ₹7.5 million, with a paid-up capital of ₹7.45 million. The workforce comprises 131 employees, indicating a stable operational scale.

The company's mission is to provide high-quality medicines at affordable prices, ensuring rigorous adherence to quality optimization in all operational aspects. Seagull Laboratories has a strong presence in the respiratory, pediatric, and gastroenterology segments, demonstrating its commitment to addressing diverse therapeutic needs.

What Does Seagull Laboratories Export? — Product Portfolio Analysis

Top Products by Export Value

1Hydroxychloroquine$153.3K 2

Product Portfolio — Top 2 by Export Value

Seagull Laboratories exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Hydroxychloroquine	Antimalarial & Antiparasitic	$153.3K	4	0.1%	10
2	Melphalan	Advanced Oncology	$100.1K	5	0.8%	8

Seagull Laboratories exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $253.4K. The top category is Antimalarial & Antiparasitic (60.5% of portfolio), followed by Advanced Oncology (39.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Seagull Laboratories — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Seagull Laboratories operates manufacturing facilities in Gurugram, Haryana, India. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the company's extensive distribution network suggests a significant manufacturing scale capable of meeting both domestic and international demands.

3Key Leadership

The leadership team at Seagull Laboratories is headed by Managing Director Mr. Devender Dogra, who has been with the company since April 1, 1994. Mr. Dogra's vision has been instrumental in steering the company towards its mission of delivering high-quality medicines. Abhinav Dogra serves as a Director, contributing to the strategic direction and growth of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Seagull Laboratories Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Seagull Laboratories' export portfolio, valued at $253,000 USD across nine shipments, includes two products: Hydroxychloroquine and Melphalan. Hydroxychloroquine, with exports totaling $153,000 USD, holds a 0.1% market share, while Melphalan, at $100,000 USD, commands a 0.8% market share. These products are primarily categorized under Antimalarial & Antiparasitic (60.5%) and Advanced Oncology (39.5%). The company's focus on these therapeutic areas indicates a strategic alignment with global health priorities. However, specific regulatory approvals or market access statuses in the US, EU, UK, Australia, and Japan are not publicly available, suggesting limited penetration in these markets.

2Emerging Markets

Seagull Laboratories has established a robust distribution network within India, comprising 20 super distributors and over 1,000 wholesalers, making its products available at more than 150,000 pharmacies nationwide. This extensive reach underscores the company's strong foothold in the domestic market. While there is no explicit information regarding the company's presence in Africa, Latin America, or Southeast Asia, the scale of its domestic operations suggests potential for expansion into these emerging markets. Achieving WHO prequalification would be a strategic move to facilitate access to these regions, aligning with the company's mission to provide high-quality medicines globally.

Seagull Laboratories — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Seagull Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. This lack of transparency may indicate limited engagement with the U.S. market. For importers and partners, it is advisable to verify the company's compliance with FDA regulations and approvals to ensure product quality and safety.

2WHO & EU GMP

There is no publicly available information confirming Seagull Laboratories' WHO prequalification or EU Good Manufacturing Practice (GMP) certifications. Obtaining these certifications would enhance the company's credibility and facilitate access to international markets. Importers should verify the company's compliance with WHO and EU GMP standards to ensure adherence to international quality benchmarks.

3CDSCO & Indian Regulatory

Seagull Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's registered address is D-3 LGF Lajpat Nagar -1, New Delhi, Delhi 110024, India. This registration indicates compliance with Indian regulatory requirements for pharmaceutical manufacturing. Importers should verify the company's CDSCO manufacturing licenses and state drug controller approvals to ensure regulatory compliance.

Seagull Laboratories — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Indian pharmaceutical market, Seagull Laboratories faces competition from both multinational corporations and domestic companies. While specific market share data is not available, the company's focus on respiratory, pediatric, and gastroenterology segments positions it in direct competition with established players in these therapeutic areas. To enhance its competitive edge, Seagull Laboratories could consider diversifying its product portfolio and expanding its presence in underrepresented markets.

2Key Differentiators

Seagull Laboratories' commitment to quality and affordability distinguishes it in the pharmaceutical industry. The company's extensive domestic distribution network, reaching over 150,000 pharmacies, underscores its strong market presence. Additionally, the leadership's vision to leverage Indian talent in competing with multinational corporations reflects a strategic approach to growth and innovation.

3Strategic Position

Currently, Seagull Laboratories focuses on manufacturing and marketing finished pharmaceutical formulations, with an emphasis on respiratory, pediatric, and gastroenterology products. The company's export activities are limited to two products, indicating a concentrated approach in international markets. Future strategic directions could involve expanding the product portfolio, obtaining international certifications, and exploring new market opportunities to enhance global presence and competitiveness.

Buyer Due Diligence Brief — Evaluating Seagull Laboratories as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Seagull Laboratories has demonstrated a consistent track record in the domestic market, with a significant distribution network and a focus on quality. The company's export volume, though modest, reflects a cautious approach to international expansion. Importers should assess the company's reliability by verifying regulatory compliance, quality certifications, and financial stability to ensure a successful partnership.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the company adheres to World Health Organization Good Manufacturing Practices. This can be verified by checking the WHO's official list of prequalified manufacturers.

Frequently Asked Questions — Seagull Laboratories

How many pharmaceutical products does Seagull Laboratories export from India?

Seagull Laboratories exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Hydroxychloroquine ($153.3K), Melphalan ($100.1K). Total export value is $253.4K.

What is Seagull Laboratories's total pharmaceutical export value?

Seagull Laboratories's total pharmaceutical export value is $253.4K, based on 9 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Seagull Laboratories cover?

Seagull Laboratories exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (60.5%, 1 products), Advanced Oncology (39.5%, 1 products).

Get Full Seagull Laboratories Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.